Trial Profile

An Open-Label, Multicenter, First-in-Human Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of SIM0610 in Adult Subjects With Locally Advanced/Metastatic Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 03 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Antineoplastics (Primary)
Indications Carcinoma; Colorectal cancer; Head and neck cancer; Liver cancer; Non-small cell lung cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions; First in man; Therapeutic Use
Acronyms SIM0610-101
Sponsors Jiangsu Simcere Pharmaceutical

27 Jan 2026 New trial record
21 Jan 2026 Simcere Zaiming media release, announced today that its bispecific antibody-drug conjugate (BsADC) SIM0610 has dosed first patient in a Phase I clinical trial at the Affiliated Cancer Hospital of Shandong First Medical University (Shandong Cancer Hospita).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com